Latest news

• Esperion gets FDA thumbs up for cholesterol drug Nexletol

  It will launch into a cholesterol market that was static for years and remains dominated by statins, but has seen a couple of new entrants – two injectable PCSK9 inhibitors from Amgen ... and Sanofi/Regeneron – and could see a launch later this year

• The Medicines Company surges on rumours of Novartis takeover

  A report from Bloomberg also suggests that other buyers are interested in MedCo as it prepares to file for approval of inclisiran – a gene-silencing drug targeting PCSK9 that can reduce ... If approved, inclisiran could pose a major challenge to

• Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

  drugs. New therapies like Novartis’ heart failure therapy Entresto (sacubitril/valsartan) and cholesterol-lowering PCSK9 inhibitors from Amgen and Sanofi/Regeneron have re-injected growth into the market, although they have

• TMC preps filings for inclisiran after final phase 3 trials hit the mark

  If approved, inclisiran will compete most closely with two antibody-based PCSK9 inhibitors – Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab) – but will offer efficacy that is at least ... Alnylam-partnered inclisiran is

• TMC rockets on data for twice-yearly cholesterol drug inclisiran

  The small, interfering RNA (siRNA) drug – which works by blocking the synthesis of PCSK9 in the liver – was being tested in patients with atherosclerotic cardiovascular disease (ASCVD) who were unable to ... That is a much less frequent dosing